TY - JOUR AB - Anthracyclines are highly effective chemotherapeutic agents, used for a wide variety of malignancies. Cardiotoxicity is a well‑recognized side effect of anthracycline therapy that limits the total amount of drug administered and can cause heart failure in some patients. Most experimental data support oxidative stress as the etiology of anthracycline‑induced cardiotoxicity. The objective of this paper was to provide a review of the clinical classification, risk factors, monitoring and prevention of anthracycline‑induced cardiotoxicity in patients with breast cancer. AD - Department of Breast Surgery, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China Department of General Practice, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China Department of Basic Medical Sciences, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China AU - Cai,Fengfeng AU - Luis,Manuel ,Antonio Falar AU - Lin,Xiaoyan AU - Wang,Minghong AU - Cai,Lu AU - Cen,Chunmei AU - Biskup,Ewelina DA - 2019/07/01 DO - 10.3892/mco.2019.1854 EP - 23 IS - 1 JO - Mol Clin Oncol KW - anthracyclines breast cancer doxorubicin cardiotoxicity risk factors prevention treatment PY - 2019 SN - 2049-9450 2049-9469 SP - 15 ST - Anthracycline‑induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment (Review) T2 - Molecular and Clinical Oncology TI - Anthracycline‑induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment (Review) UR - https://doi.org/10.3892/mco.2019.1854 VL - 11 ER -